It is single-dose of COVID-19 vaccine from Johnson & Johnson that  showed strong promise against the Delta variant and other emerging strains and also provided durable protection against the infection more broadly, the company said on Thursday.

The healthcare company said that the durability of immune response for recipients of its vaccine lasted at least eight months, adding that its vaccine was 85 percent effective and could also help prevent hospitalization and death.

First identified in India, Delta is becoming the globally dominant variant of the coronavirus, according to the World Health Organization.

“Current data for the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” Mathai Mammen, head of research & development at J&J’s drugs business, said in the statement.